---
title: "Imsidolimab in Generalized pustular psoriasis: References"
description: "Reference list for the formulary evidence report on Imsidolimab in Generalized pustular psoriasis. 83 cited documents."
canonical: "https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/references"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Imsidolimab in Generalized pustular psoriasis: References

<a id="references"></a>

## 5 References

1. [AnaptysBio (2017)](https://ir.anaptysbio.com/news-releases/news-release-details/anaptysbio-reports-positive-anb019-top-line-phase-1-clinical)
2. [AnaptysBio (2018)](https://ir.anaptysbio.com/news-releases/news-release-details/anaptysbio-presents-updated-anb020-and-anb019-clinical-data-2018/)
3. [AnaptysBio (2020)](https://ir.anaptysbio.com/news-releases/news-release-details/anaptysbio-reports-positive-topline-data-gallop-phase-2-clinical)
4. [AnaptysBio (2021)](https://ir.anaptysbio.com/news-releases/news-release-details/anaptysbio-presents-updated-data-imsidolimab-phase-2-gallop)
5. [AnaptysBio (2024)](https://ir.anaptysbio.com/news-releases/news-release-details/anaptys-announces-positive-top-line-gemini-2-phase-3-clinical)
6. [AnaptysBio British Journal of Dermatology publication announcement (2023)](https://ir.anaptysbio.com/news-releases/news-release-details/anaptysbio-announces-british-journal-dermatology-publication)
7. [AnaptysBio phase 3 topline results announcement (2023)](https://ir.anaptysbio.com/news-releases/news-release-details/anaptys-announces-positive-top-line-phase-3-clinical-trial/)
8. [ANZCTR ACTRN12617000369325](https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12617000369325)
9. [ANZCTR NCT05352893](https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=20464&isClinicalTrial=True)
10. [Armstrong et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37838256/)
11. [Bachelez et al. (2021)](https://eprints.gla.ac.uk/262088/1/262088.pdf)
12. [Barker et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39844356/)
13. [Bhutani and Farberg (2024)](https://link.springer.com/article/10.1007/s13555-024-01103-5)
14. [Bulai Livideanu et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11806833/)
15. [Burden et al. (2023)](https://onlinelibrary.wiley.com/doi/full/10.1111/jdv.18999)
16. [Chen et al. (2024)](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1462158/full)
17. [Chien et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13319885/)
18. [Choon et al. (2021)](https://eprints.gla.ac.uk/238653/1/238653.pdf)
19. [Choon et al. (2023)](https://karger.com/drm/article/239/3/345/835953/Clinical-Characteristics-and-Outcomes-of)
20. [Choon et al. (2024a)](https://onlinelibrary.wiley.com/doi/10.1111/jdv.19530)
21. [Choon et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38691347/)
22. [Choon et al. (2024c)](https://onlinelibrary.wiley.com/doi/full/10.1111/1346-8138.17471)
23. [ClinicalTrials.gov NCT03619902](https://clinicaltrials.gov/study/NCT03619902)
24. [ClinicalTrials.gov NCT03619902 protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/02/NCT03619902/Prot_000.pdf)
25. [ClinicalTrials.gov NCT05352893](https://clinicaltrials.gov/study/NCT05352893)
26. [ClinicalTrials.gov NCT05352893 protocol](https://cdn.clinicaltrials.gov/large-docs/93/NCT05352893/Prot_000.pdf)
27. [ClinicalTrials.gov NCT05352893 statistical analysis plan (2022)](https://cdn.clinicaltrials.gov/large-docs/93/NCT05352893/SAP_001.pdf)
28. [ClinicalTrials.gov NCT05366855](https://clinicaltrials.gov/study/NCT05366855)
29. [ClinicalTrials.gov NCT05366855 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/55/NCT05366855/Prot_000.pdf)
30. [ClinicalTrials.gov NCT05366855 statistical analysis plan (2022)](https://cdn.clinicaltrials.gov/large-docs/55/NCT05366855/SAP_001.pdf)
31. [DailyMed SPEVIGO prescribing information (2026)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=41a481ee-3062-45d1-aed5-17e8b105634d)
32. [Frysz et al. (2024)](https://academic.oup.com/bjd/article/191/4/529/7679321)
33. [Fujita et al. (2018)](https://onlinelibrary.wiley.com/doi/10.1111/1346-8138.14523)
34. [Gleeson and Mahil (2023)](https://pubmed.ncbi.nlm.nih.gov/37079741/)
35. [Gottlieb et al. (2025)](https://journals.sagepub.com/doi/10.1177/24755303251344155)
36. [Gudjonsson et al. (2022)](https://www.jaad.org/article/S0190-9622%2822%2901361-5/fulltext)
37. [Hagenström et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40689154/)
38. [Hanna et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33622113/)
39. [Kam et al. (2024)](https://doi.org/10.1016/j.jaad.2024.07.1134)
40. [Khanskaya et al. (2018)](https://www.anaptysbio.com/wp-content/uploads/ANB019-Phase-1-Study-Poster-EAACI-2018.pdf)
41. [Kole et al. (2025)](https://link.springer.com/article/10.1007/s13555-025-01483-2)
42. [Lebwohl et al. (2025)](https://www.sciencedirect.com/science/article/pii/S0190962225025381)
43. [Lin et al. (2026)](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1885617/full)
44. [Lynde et al. (2025)](https://link.springer.com/article/10.1007/s13555-025-01535-7)
45. [Marrakchi et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21848462/)
46. [Miyachi et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34116101/)
47. [Morita et al. (2022)](https://link.springer.com/article/10.1007/s13555-022-00835-6)
48. [Morita et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37738999/)
49. [Morita et al. (2026)](https://medicaljournalssweden.se/actadv/article/view/45960)
50. [National Health Care Institute horizon scan (2026)](https://www.horizonscangeneesmiddelen.nl/geneesmiddelen/imsidolimab?versie=versie-3)
51. [Navarini et al. (2017)](https://onlinelibrary.wiley.com/doi/full/10.1111/jdv.14386)
52. [NICE (2026)](https://www.ncbi.nlm.nih.gov/books/NBK623517/)
53. [Noe et al. (2022)](https://www.med.upenn.edu/gelfand/assets/user-content/evaluation-of-a-case-series-of-patients-with-generalized-pustular-psoriasis-in-the-united-states.pdf)
54. [Noe et al. (2025)](https://journals.sagepub.com/doi/10.1177/24755303251317193)
55. [Norlin et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11095275/)
56. [Patel et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36922363/)
57. [Puig et al. (2023)](https://onlinelibrary.wiley.com/doi/full/10.1111/jdv.18851)
58. [Puig et al. (2024)](https://link.springer.com/article/10.1007/s13555-024-01230-z)
59. [Reich et al. (2024)](https://www.anaptysbio.com/wp-content/uploads/1058_EADV2024_Reich_Imsidolimab-Ph3_Final.pdf)
60. [Seah et al. (2025a)](https://link.springer.com/article/10.1186/s13023-025-03820-2)
61. [Seah et al. (2025b)](https://link.springer.com/article/10.1186/s13561-025-00670-3)
62. [Smieszek et al. (2025)](https://www.jidonline.org/article/S0022-202X%2825%2903089-1/fulltext)
63. [Smieszek et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42047557/)
64. [Strober et al. (2026a)](https://www.sciencedirect.com/science/article/pii/S0190962225027252)
65. [Strober et al. (2026b)](https://link.springer.com/article/10.1007/s13555-025-01584-y)
66. [Sugiura et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23698098/)
67. [Tada et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11483928/)
68. [Teitsma et al. (2026)](https://medicaljournalssweden.se/actadv/article/view/44671)
69. [Vanda Pharmaceuticals BLA acceptance announcement (2026)](https://vandapharmaceuticalsinc.gcs-web.com/node/16791/pdf)
70. [Vanda Pharmaceuticals BLA submission announcement (2025)](https://www.prnewswire.com/news-releases/vanda-announces-submission-of-biologics-license-application-to-the-fda-for-imsidolimab-for-the-treatment-of-generalized-pustular-psoriasis-302641858.html)
71. [Vanda Pharmaceuticals earnings call transcript (2026)](https://www.investing.com/news/transcripts/earnings-call-transcript-vanda-pharmaceuticals-q1-2026-misses-eps-forecast-stock-drops-93CH-4680843)
72. [Vanda Pharmaceuticals EMA orphan designation opinion announcement (2026)](https://vandapharmaceuticalsinc.gcs-web.com/node/17086/pdf)
73. [Vanda Pharmaceuticals European Commission orphan designation announcement (2026)](https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-granted-orphan-designation-for-imsidolimab-for-the-treatment-of-generalized-pustular-psoriasis-by-the-european-commission-302857847.html)
74. [Vanda Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1347178/000162828026007460/vnda-20251231.htm)
75. [Vanda Pharmaceuticals Form 8-K (2026)](https://www.sec.gov/Archives/edgar/data/0001347178/000162828026067886/vnda8-k10282026exhibit991.htm)
76. [Vanda Pharmaceuticals Japan orphan drug designation announcement (2026)](https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-orphan-drug-designation-in-japan-for-imsidolimab-in-generalized-pustular-psoriasis-302782517.html)
77. [Vanda Pharmaceuticals license agreement announcement (2025)](https://vandapharmaceuticalsinc.gcs-web.com/node/16241/pdf)
78. [Vanda Pharmaceuticals NEJM Evidence publication announcement (2026)](https://vandapharmaceuticalsinc.gcs-web.com/node/16946/pdf)
79. [Vanda Pharmaceuticals second quarter 2026 results announcement (2026)](https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-reports-second-quarter-2026-financial-results-302844175.html)
80. [Viguier et al. (2024)](https://onlinelibrary.wiley.com/doi/full/10.1111/jdv.19901)
81. [Viguier et al. (2026)](https://link.springer.com/article/10.1007/s13555-026-01691-4)
82. [Warren et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37120722/)
83. [Zema et al. (2022)](https://jamanetwork.com/journals/jamadermatology/fullarticle/2794824)

## Related pages
- [Imsidolimab: Generalized pustular psoriasis](https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis) · [Markdown](https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis.md)
- [Imsidolimab in Generalized pustular psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/terms-and-abbreviations.md)
- [Imsidolimab: Generalized pustular psoriasis](https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/executive-summary.md)
- [Imsidolimab in Generalized pustular psoriasis: Product information and disease description](https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/product-information-and-disease-description.md)
- [Imsidolimab in Generalized pustular psoriasis: Clinical evidence](https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/clinical-evidence.md)
- [Imsidolimab in Generalized pustular psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/economics.md)
- [Imsidolimab in Generalized pustular psoriasis: prevalence by geography](https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/prevalence) · [Markdown](https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/prevalence.md)
- [Imsidolimab in Generalized pustular psoriasis: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/cost-effectiveness-analyses.md)
